Begin main content

Reports

We found 4861 result(s)

Emerging Drug List — Alemtuzumab for B-cell chronic lymphocytic leukemia

Published on: May 20, 2004
Result type: Reports
Product Line: Emerging Drug List

Tags

Antibodies, Antineoplastic Agents, Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoblastic Leukemia, Lymphocytic Leukemia, Cancer, Antibodies, Monoclonal, Antibodies, Neoplasm, Leukemia, B-Cell, Chronic, Leukemia, Lymphoblastic, Chronic, Leukemia, Lymphocytic, Chronic, Lymphoblastic Leukemia, Chronic, Lymphocytic Leukemia, Chronic, Apoptosis, Blood, Cancer, Monoclonal, Anticorps monoclonal, humanized anti-CD52 monoclonal antibody, Alemtuzumab, Campath, MabCampath, Neoplasm, Anticorps antitumoral, Antinéoplasiques Antirheumatic Agents, Agents antirhumatismaux, B-Cell, Chronic, Leucémie B chronique, B-cell chronic leukaemia, B-cell chronic leukemia, B-cell chronic lymphocytic leukaemia, B-CLL, Lymphocytic, Leucémie lymphocytaire chronique, chronic lymphoblastic leukaemia, chronic lymphoblastic leukemia, CLL, leukaemia, lymphoblastic, chronic, lymphoblastic leukaemia, lymphocytic leukaemia

Peginterferon alfa-2a and Ribavirin (Pegasys RBV)

Last Updated: May 14, 2004
Result type: Reports
Product Line: Common Drug Review
Generic Name: Peginterferon alfa-2a and Ribavirin
Indications: Hepatitis C, chronic

  • Brand Name: Pegasys RBV
  • Manufacturer: Hoffman-La Roche Ltd.
  • Project Number: S0013
  • Project Status: Complete
  • Submission Type: New

Inteferon-based therapies for chronic Hepatitis C virus infection: an assessment of clinical outcomes

Published on: May 13, 2004
Result type: Reports
Product Line: Health Technology Assessment, Technology Reports

Technology Name Interferon (IFN)-based antiviral therapies: standard IFN plus ribavirin versus standard IFN therapy alone standard IFN plus ribavirin versus pegylated IFN plus ribavirin Disease/Condition Chronic hepatitis C virus (HCV) infection Technology Description IFNs are human proteins that inhibit virus replication in infected cells and b...

Tags

Drug Therapy, Hepatitis C, Chronic Hepatitis C, Interferon-alpha, Interferons, Ribavirin, Treatment Outcome, Hepatitis, Hepatitis C, Chronic, Hepatitis, Combination, Polychimiothérapie, Chronic, Hépatite C chronique, chronic HCV, chronic HCV infection, HCV infection, Chronic Hepatitis C infection, Chronic Hepatitis C virus, Interféron-alpha IFN-alpha, IFN-based therapy, IFN-based therapies, IFN therapy, interferon-based therapy, interferon-based therapies, interferon therapy, Ribavirine Rebetron, Évaluation résultats traitement, clinical outcomes

Miglustat (Zavesca)

Last Updated: May 13, 2004
Result type: Reports
Product Line: Common Drug Review
Generic Name: Miglustat
Indications: Gaucher disease

  • Brand Name: Zavesca
  • Manufacturer: Actelion Pharmaceuticals Canada Inc.
  • Project Number: S0012
  • Project Status: Complete
  • Submission Type: New

Impact of radiation wait times on risk of local recurrence of breast cancer: early stage cancer with no chemotherapy

Published on: May 5, 2004
Result type: Reports
Product Line: Health Technology Assessment, Technology Reports

Technology Name Radiation therapy; typically whole breast radiation after breast conservation surgery (BCS) with or without additional irradiation (boost radiation) localized at the surgery site. Disease/Condition Early stage breast cancer (stages I and II) with no chemotherapy. Technology Description Radiation therapy (RT) involves the use of g...

Tags

Breast Neoplasms, Breast Cancer, Cancer of Breast, Cancer of the Breast, Human Mammary Carcinoma, Human, Mammary Neoplasms, Neoplasms, Breast, Disease Progression, Drug Therapy, Chemotherapy, Mastectomy, Breast-Conserving Surgery, Lumpectomy, Partial Mastectomy, Local Excision Mastectomy, Segmentectomy, Outcome Assessment (Health Care), Radiation Oncology, Radiation, Radiotherapy, Recurrence, Risk, Survival Rate, Time Factors, Waiting Lists, Neoplasms, Breast, Mammary Carcinoma, Human, Mammary Neoplasms, Human, Neoplasm Recurrence, Local, Mastectomy, Segmental, Surgery, Breast-Conserving, Breast cancer, Surgery, systematic review, Tumeur sein, mammary carcinoma, Progression maladie, Chimiothérapie, Segmental, Mastectomie partielle, breast conserving surgery, breast-conserving, Neoplasm Recurrence, Local, Récidive tumorale locale, local recurrence, Stade cancer, early stage cancer, Stage I cancer, Stage II cancer, Évaluation résultats (santé), patient outcomes, Radiothérapie carcinologique, Radiothérapie, radiation therapy, Récidive, Risque, Taux survie, Facteur temps, delayed access, Liste attente, wait lists, wait times, waiting times

Gefitinib for advanced or metastatic non-small cell lung cancer

Published on: April 14, 2004
Result type: Reports

Summary Gefitinib is approved as monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have failed prior platinum-based treatment and docetaxel chemotherapy.1 Its efficacy when compared to standard treatment and best supportive care is unproven. Common drug-related adverse effects incl...

Tags

Carcinoma, Lung Cancer, Epidermal Growth Factor, Quinazolines, Carcinoma, Non-Small-Cell Lung, Lung cancer, Non-Small-Cell Lung, Carcinome bronchique nonpetites cellules, advanced non-small cell, metastatic, NSCLC, Facteur croissance epidermique, epidermal growth factor receptor inhibitor, epidermal growth factor receptor inhibitors, epidermal growth factor receptor tyrosine kinase inhibitor, epidermal growth factor receptor tyrosine kinase inhibitors, gefitinib, Iressa, anilinoquinazoline

Mixed amphetamine salts (Adderall XR)

Last Updated: April 13, 2004
Result type: Reports
Product Line: Common Drug Review
Generic Name: Mixed amphetamine salts
Indications: Attention deficit hyperactivity disorder

  • Brand Name: Adderall XR
  • Manufacturer: Shire BioChem Inc.
  • Project Number: S0010
  • Project Status: Complete
  • Submission Type: New

Prolotherapy for the treatment of chronic musculosketal pain

Published on: March 31, 2004
Result type: Reports
Product Line: Preassessments

Tags

Anesthetics, Injections, Low Back Pain, Pain, Chronic Pain, Sclerosing Solutions, Solutions, Musculoskeletal Pain, Musculoskeletal, Anesthésiques, Growth Substances Substances croissance, Injection, prolotherapy, Lombalgie, chronic low back pain, Aliment, chronic musculosketal pain, Sclérosant, proliferants

Pegfilgrastim (Neulasta)

Last Updated: March 29, 2004
Result type: Reports
Product Line: Common Drug Review
Generic Name: Pegfilgrastim
Indications: Neutropenia

  • Brand Name: Neulasta
  • Manufacturer: Amgen Canada Inc.
  • Project Number: S0009
  • Project Status: Complete
  • Submission Type: New

Gastroduodenal ulcers associated with the use of non-steroidal anti-inflammatory drugs: a systematic review of preventive pharmacological interventions

Published on: March 10, 2004
Result type: Reports
Product Line: Health Technology Assessment, Technology Overviews

Technology Name Non-steroidal anti-inflammatory drugs (NSAIDs) Gastroprotective agents: misoprostol, histamine type-2 receptor antagonists (H2RAs), proton pump inhibitors (PPIs) Cyclooxygenase (COX)-2 selective NSAIDs: celecoxib, rofecoxib, meloxicam. Disease/Condition Traditional NSAIDs, which are used to treat painful arthritic and infla...

Tags

Gastritis, Peptic Ulcer Perforation, Anti-Inflammatory Agents, Anti-Ulcer Agents, Prostaglandin Antagonists, Proton Pumps, Histamine H2 Antagonists, Misoprostol, Etodolac, Esomeprazole, Gastrointestinal Tract, Anti-Inflammatory Agents, Non-Steroidal, Gastroduodenal Ulcer, Gastrointestinal tract, Gastrite Gastroduodenal ulcers Gastrointestinal hemorrhage, Hémorragie gastrointestinale Gi bleeds, Perforation ulcère gastroduodénal Gi hemorrhage, Peptic ulcer Ulcère gastroduodénal Gastrointestinal bleeding, non-steroidal, Antiinflammatoires nonsteroidiens Ulcer hemorrhage, Antiulcereux Gastrointestinal performation, Antagonistes prostaglandine Nonsteroidal anti-inflammatories, Pompe à protons Cyclo oxygenase inhibitors, Antihistaminiques récepteurs H2 Cyclooxygenase inhibitors, Misoprostol celecoxib, celebrex, rofecoxib, vioxx, meloxicam, pantoprazole, lansoprazole, timoprazole, rabeprazole